(Q36152211)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21604939%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

title

Developing imaging strategies for castration resistant prostate cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21604939%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21604939%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

3

Steven M Larson

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21604939%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

5

Howard I Scher

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21604939%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1

Josef J Fox

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21604939%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

author name string

Heiko Schöder

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21604939%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

publication date

1 June 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21604939%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21604939%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

volume

50 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21604939%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

page(s)

39-48

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21604939%20AND%20SRC:MED&resulttype=core&format=json

Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancer

1 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3415271

Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST.

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3415271

89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo.

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3415271

AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3415271

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3415271

Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3415271

Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3415271

Pharmacokinetic assessment of the uptake of 16beta-18F-fluoro-5alpha-dihydrotestosterone (FDHT) in prostate tumors as measured by PET.

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3415271

Two Cases of Cancer of Prostate with Bony Metastases.

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3415271

Measuring therapeutic efficacy in the changing paradigm of castrate-resistant prostate cancer

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3415271

Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3415271

Understanding the Warburg effect: the metabolic requirements of cell proliferation

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3415271

From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3415271

Improved classifications of planar whole-body bone scans using a computer-assisted diagnosis system: a multicenter, multiple-reader, multiple-case study

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3415271

Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research.

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3415271

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3415271

Novel tracers and their development for the imaging of metastatic prostate cancer

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3415271

Targeting the androgen receptor pathway in prostate cancer

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3415271

Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapy

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3415271

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3415271

Strategic paths for biomarker qualification

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3415271

Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials.

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3415271

Prostate cancer clinical trial end points: "RECIST"ing a step backwards.

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3415271

Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy.

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3415271

Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3415271

Positron tomographic assessment of androgen receptors in prostatic carcinoma

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3415271

Molecular determinants of resistance to antiandrogen therapy

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3415271

Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis.

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3415271

Prostate carcinoma: defining therapeutic objectives and improving overall outcomes

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3415271

The development of androgen-independent prostate cancer

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3415271

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3415271

The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3415271

Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3415271

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3415271

Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer.

2 July 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.572914

Computer-assisted interpretation of planar whole-body bone scans.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.572914

Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.572914

A Coordinate System for Tumor Identification in Positron Emission Tomography (PET) Imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.572914

Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.572914

18F-FDG PET as a candidate for "qualified biomarker": functional assessment of treatment response in oncology.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3415271

The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3415271

Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3415271

A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3415271

Quantitative bone metastases analysis based on image segmentation.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3415271

A New Complex of99mTc for Skeletal Imaqinq

23 September 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.572914

Clinical states in prostate cancer: toward a dynamic model of disease progression

21 January 2018

1 reference

12 December 2020

Detection of bony metastases of androgen-independent prostate cancer by PET-FDG

1 reference

12 December 2020

The flare phenomenon on radionuclide bone scan in metastatic prostate cancer

1 reference

12 December 2020

Comparative value of bone scintigraphy and radiography in monitoring tumor response in systemically treated prostatic carcinoma

1 reference

12 December 2020

Fluorine-18: a new isotope for bone scanning

1 reference

12 December 2020

Surrogate and mediating endpoints: current status and future directions

1 reference

12 December 2020

Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose

1 reference

12 December 2020

Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding

1 reference

12 December 2020

Fluorine-18-labeled androgens: radiochemical synthesis and tissue distribution studies on six fluorine-substituted androgens, potential imaging agents for prostatic cancer

1 reference

12 December 2020

Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs

1 reference

12 December 2020

10.3109/0284186X.2011.572914

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21604939%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21604939%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

PubMed publication ID

21604939

1 reference